[Retracted] Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

Table 2

Expression of MMP-2 and VEGF after RZD and GW9662 cotreatment in SGC-7901 by real-time PCR.

Rosiglitazone (𝜇mol/L)	PPAR𝛾	MMP-2
0	0.14161±0.055389	0.00975±0.000533
1	0.137738±0.030102	0.008974±0.000113^*
3	0.134614±0.029881	0.006003±0.000401^*
5	0.141156±0.564569	0.00564±0.000246^*
10	0.135666±0.034887	0.002182±0.000364^*
20	0.129278±0.019262	0.001712±0.000178^*

^*Statistical significance (𝑃<.05 or higher degree of significance) versus vehicle-treated controls.